Deciphera Pharmaceuticals, Inc.

NasdaqGS:DCPH Stok Raporu

Piyasa değeri: US$2.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Deciphera Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Deciphera Pharmaceuticals CEO'su Steve Hoerter, Mar2019 tarihinde atandı, in görev süresi 5.25 yıldır. in toplam yıllık tazminatı $ 6.01M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.3% maaş ve 87.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.084% ine doğrudan sahiptir ve bu hisseler $ 1.86M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 9 yıldır.

Anahtar bilgiler

Steve Hoerter

İcra Kurulu Başkanı

US$6.0m

Toplam tazminat

CEO maaş yüzdesi12.28%
CEO görev süresi5.3yrs
CEO sahipliği0.08%
Yönetim ortalama görev süresi4.3yrs
Yönetim Kurulu ortalama görev süresi9yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • Apr 30

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Deciphera Pharmaceuticals, Inc. ( NASDAQ:DCPH ) shares have continued their recent momentum with a 61% gain in the last...
Seeking Alpha • Apr 26

Diving Into Deciphera Pharmaceuticals

Summary Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT. Vimseltinib is expected to make significant progress in the TGCT indication, as the only approved therapy is under a Risk Evaluation and Mitigation Strategy protocol. Deciphera's switch-control kinase inhibitor platform aims to produce compounds that target specific regions of kinases, resulting in higher activity and lower toxicity compared to current kinase inhibitors. An investment analysis around Deciphera Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Dec 02

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analiz Makalesi • Sep 25

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Key Insights Deciphera Pharmaceuticals' estimated fair value is US$21.93 based on 2 Stage Free Cash Flow to Equity...
Analiz Makalesi • Jul 26

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Jun 22

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Key Insights Deciphera Pharmaceuticals' estimated fair value is US$16.23 based on 2 Stage Free Cash Flow to Equity...
Analiz Makalesi • May 08

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

Deciphera Pharmaceuticals, Inc.'s ( NASDAQ:DCPH ) price-to-sales (or "P/S") ratio of 7.7x might make it look like a buy...
Analiz Makalesi • Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Dec 29

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals (NASDAQ:DCPH) has been initiated as a buy at Cowen based on growth in sales of its advanced gastrointestinal stromal tumor treatment Qinlock (ripretinib) and its pipeline. The firm has a $25 price target (~68% upside based on Friday's close). Analyst Tyler Van Buren said that Decipera (DCPH) pipeline is "poised to break out" and a significant catalyst could come next month at the European Society for Medical Oncology (ESMO) annual meeting with data on vimseltinib and DCC-3116. Vimseltinib is in phase 1/2 for tenosynovial giant cell tumor, while DCC-3116 is in phase 1 for RAS/RAF mutant cancers in combination with Mekinist (trametinib). He added he sees peak sales of both candidates at a combined ~$1.3B. Seeking Alpha's Quant Rating view Deciphera as a buy with high marks for momentum, growth, and revisions.
Seeking Alpha • Aug 03

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is -$0.67 (vs. -$1.21 last year) and the consensus Revenue Estimate is $30.11M (+27.7% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions and 3 downward. Revenue estimates have seen 5 upward revisions and 3 downward.
Analiz Makalesi • Jul 29

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Feb 11

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera's ripretinib failed a critical trial. The stock has been decimated. Although the company is struggling to make a comeback, it will take time.
Seeking Alpha • Nov 22

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST. With buoying expenses, Deciphera needs to make a splash to increase revenues quickly, or else dilution is a serious risk. Though risky overall, Deciphera at these levels presents a very interesting risk/benefit case.
Analiz Makalesi • Aug 26

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • May 10

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

CEO Tazminat Analizi

Steve Hoerter'un ücretlendirmesi Deciphera Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2024n/an/a

-US$190m

Dec 31 2023US$6mUS$738k

-US$195m

Sep 30 2023n/an/a

-US$194m

Jun 30 2023n/an/a

-US$187m

Mar 31 2023n/an/a

-US$182m

Dec 31 2022US$4mUS$703k

-US$179m

Sep 30 2022n/an/a

-US$221m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$9mUS$676k

-US$300m

Sep 30 2021n/an/a

-US$274m

Jun 30 2021n/an/a

-US$258m

Mar 31 2021n/an/a

-US$255m

Dec 31 2020US$8mUS$650k

-US$266m

Sep 30 2020n/an/a

-US$271m

Jun 30 2020n/an/a

-US$263m

Mar 31 2020n/an/a

-US$218m

Dec 31 2019US$9mUS$435k

-US$192m

Sep 30 2019n/an/a

-US$157m

Jun 30 2019n/an/a

-US$126m

Mar 31 2019n/an/a

-US$126m

Dec 31 2018US$447kn/a

-US$100m

Tazminat ve Piyasa: Steve 'ın toplam tazminatı ($USD 6.01M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 5.45M ).

Tazminat ve Kazançlar: Steve şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Steve Hoerter (53 yo)

5.3yrs
Görev süresi
US$6,010,712
Tazminat

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Steven Hoerter
President5.3yrsUS$6.01m0.084%
$ 1.9m
Thomas Kelly
Executive VP9.3yrsUS$2.03m0.049%
$ 1.1m
Dashyant Dhanak
Executive VP & Chief Scientific Officerless than a yearUS$3.06m0%
$ 0
Daniel Martin
Senior VP & Chief Commercial Officer5.8yrsUS$1.58m0.036%
$ 801.7k
Matthew Sherman
Executive VP & Chief Medical Officer4.7yrsUS$2.13m0.084%
$ 1.8m
Kevin Brodbeck
Senior VP & Chief Technical Officerless than a yearVeri yokVeri yok
Jennifer Larson
Senior Vice President of Finance & Investor Relationsno dataVeri yokVeri yok
Jeffrey Held
Senior VP & General Counsel5.3yrsVeri yokVeri yok
Lisa Price
Senior VP & Chief Human Resources Officer2.4yrsVeri yokVeri yok
Jama Pitman
Senior VP & Chief Development Officer4.3yrsVeri yok0.040%
$ 876.3k
Margarida Duarte
Senior VP & Head of International3.3yrsVeri yokVeri yok
Rodrigo Soto
Senior Vice President of Clinical Development3.4yrsVeri yokVeri yok
4.3yrs
Ortalama Görev Süresi
53yo
Ortalama Yaş

Deneyimli Yönetim: DCPH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Steven Hoerter
President6.1yrsUS$6.01m0.084%
$ 1.9m
John Martin
Independent Director9.3yrsUS$388.59k0%
$ 0
Edward Benz
Independent Director7.7yrsUS$396.09k0%
$ 0
Patricia L. Allen
Independent Director7.8yrsUS$398.55k0%
$ 0
Ron Squarer
Independent Chairman4.5yrsUS$403.30k0%
$ 0
Jean-Yves Blay
Member of Scientific Advisory Board9yrsVeri yokVeri yok
James Bristol
Independent Director16.8yrsUS$414.77k0%
$ 0
John Condeelis
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Filip Janku
Member of Scientific Advisory Board9yrsVeri yokVeri yok
F. Hodi
Member of Scientific Advisory Board9yrsVeri yokVeri yok
Dennis Walsh
Independent Director9.3yrsUS$386.05k0.013%
$ 281.5k
John de Groot
Member of Scientific Advisory Boardno dataVeri yokVeri yok
9.0yrs
Ortalama Görev Süresi
62yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: DCPH 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2024/06/11 17:12
Gün Sonu Hisse Fiyatı2024/06/11 00:00
Kazançlar2024/03/31
Yıllık Kazançlar2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Deciphera Pharmaceuticals, Inc. 15 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Madhu KumarB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.